Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Human immunodeficiency virus (HIV) quasispecies diversity presents a large barrier to the eradication of HIV. The aim of this study was to investigate intrahost HIV quasispecies diversity and evolutionary patterns underpinning the mechanisms of viral pathogenesis during antiretroviral therapy (ART).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Forty-five participants with HIV-1 infection were enrolled in a follow-up cohort for >84 months in 2004, and received a lamivudine-based first-line ART regimen. Blood samples were collected every 6 months to measure viral load and CD4<sup>+</sup> cell count. Ultra-deep sequencing and phylogenetic analysis were used to characterize the dynamics governing quasispecies diversity of HIV-1 circulating between plasma RNA and cellular DNA of participants with treatment failure (TF, <em>n</em> = 20) or virologic suppression (VS, <em>n</em> = 25).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Analysis of the distribution of intrahost single-nucleotide variations (iSNVs) and their mutated allele frequencies revealed that approximately 65% of the quasispecies co-occurred in plasma HIV RNA and cellular DNA either before or after ART. The number and frequency of iSNVs are more representative of intrahost HIV diversity, and have better generalizability than phylogenetic inference by measurement of phylogenetic associations. Furthermore, drug-resistance-associated mutations (DRAMs) accumulated to high levels, dramatically increasing the DRAM-to-total-mutation ratio for TF patients. Linear regression analysis revealed that emergent mutations accumulated faster in TF patients compared with VS patients, at a rate of 0.02 mutations/day/kb.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Based on iSNV analysis, the results demonstrate the dynamics of intrahost HIV quasispecies diversity in patients on ART, and provide a novel insight into the persistence of HIV and development of DRAMs.</p>

Identification of HIV Rapid Mutations Using Differences in Nucleotide Distribution over Time.

Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure

In-depth investigation of the point mutation pattern of HIV-1

Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

Large Evolutionary Rate Heterogeneity among and within HIV-1 Subtypes and CRFs

In-vivo mutation rates and fitness landscape of HIV-1

Host-specific Driving Force in Human Immunodeficiency Virus Type 1 Evolution in Vivo.

Recombination Rate and Selection Strength in HIV Intra-patient Evolution

Using A Mutual Information-Based Site Transition Network to Map the Genetic Evolution of Influenza A/H3n2 Virus

[Dynamic Variation of HIV-1 CRF07_BC Env Gene in Early HIV-1 Infection].

Trace the History of HIV and Predict Its Future Through Genetic Sequences

Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the Nef Gene of HIV-1.

Mutations on COVID-19 diagnostic targets

Worldwide tracing of mutations and the evolutionary dynamics of SARS CoV 2

Dynamics of HIV-1 quasispecies diversity of participants on long-term antiretroviral therapy based on intrahost single-nucleotide variations

Discontinuous Sequence Change of Human Immunodeficiency Virus (HIV) Type 1 Env Sequences in Plasma Viral and Lymphocyte-Associated Proviral Populations in Vivo: Implications for Models of HIV Pathogenesis.

Inspecting the interaction between HIV and the immune system through genetic turnover

Patterns of HIV-1 Evolution in Individuals with Differing Rates of CD4 T Cell Decline

Detecting and Understanding Combinatorial Mutation Patterns Responsible for HIV Drug Resistance

Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy's outcome for HIV-1

Loss and Recovery of Genetic Diversity in Adapting Populations of HIV